Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury

• Status: Withdrawn
• Trial end date: 2019-05-15
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial studies how well arginine works in treating patients with kidney injury caused by anti-VEGF drugs used in standard treatment for cancer. Arginine is a nutritional supplement that may control side effects of anti-cancer drugs such as high blood pressure and protein in the urine and may also help to improve kidney function in patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Endothelial Growth Factors

Criteria

Inclusion Criteria:

• On or enrolled for anti-VEGF therapy

• Systolic Blood Pressure >= 140 mm Hg

• Diastolic Blood Pressure >= 90 mm Hg

• Proteinuria >= 500 mg/day or worsening glomerular filtration rate (GFR) (> 0.3 mg/dl in 48 hours [hrs.] or > 50% decline from baseline creatinine in 1 week)

Exclusion Criteria:

• Allergy to L-arginine

• Systolic Blood Pressure < 140 mm Hg

• Diastolic Blood Pressure < 90 mm Hg

• Proteinuria < 500 mg/day

• Continuous tube feeds (since the medication will be given in-between meals)